Sarepta Therapeutics (SRPT) Accounts Payables (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Accounts Payables of $70.4 million for Q1 2026, down 54.92% year-over-year from $156.1 million in Q1 2025, and down 74.94% quarter-over-quarter from $280.8 million in Q4 2025.
Sarepta Therapeutics (SRPT) Accounts Payables (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Accounts Payables history runs 17 years deep, the most recent figure standing at $70.4 million for Q1 2026.
- In Q1 2026, Accounts Payables fell 54.92% year-over-year to $70.4 million; the TTM figure through Mar 2026 stood at $70.4 million (down 54.92% YoY), while the FY2025 annual figure was $280.8 million, up 30.96% from the prior year.
- Accounts Payables for Q1 2026 stood at $70.4 million, down from $280.8 million in the prior quarter.
- The five-year high for Accounts Payables was $280.8 million in Q4 2025, with the low at $54.0 million in Q1 2022.
- The 5-year median for Accounts Payables is $107.4 million (2024), against an average of $121.4 million.
- The sharpest annual moves came in 2022 and 2026: Accounts Payables jumped 168.24% in 2022, then plunged 54.92% in 2026.
- Sarepta Therapeutics' Accounts Payables stood at $95.9 million in 2022, then surged by 72.01% to $164.9 million in 2023, then soared by 30.03% to $214.4 million in 2024, then surged by 30.96% to $280.8 million in 2025, then plunged by 74.94% to $70.4 million in 2026.
- Business Quant data shows SRPT's Accounts Payables at $70.4 million in Q1 2026, $280.8 million in Q4 2025, and $94.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | 50.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.98 Mn |
| Mar 31, 2026 | 70.38 Mn |
| Dec 31, 2025 | 280.84 Mn |
| Sep 30, 2025 | 94.02 Mn |
| Jun 30, 2025 | 136.70 Mn |
| Mar 31, 2025 | 156.11 Mn |
| Dec 31, 2024 | 214.44 Mn |
| Sep 30, 2024 | 118.77 Mn |
| Jun 30, 2024 | 107.42 Mn |
| Mar 31, 2024 | 91.54 Mn |
| Dec 31, 2023 | 164.92 Mn |
| Sep 30, 2023 | 87.95 Mn |
| Jun 30, 2023 | 109.80 Mn |
| Mar 31, 2023 | 106.71 Mn |
| Dec 31, 2022 | 95.88 Mn |
| Sep 30, 2022 | 118.46 Mn |
| Jun 30, 2022 | 56.21 Mn |
| Mar 31, 2022 | 54.01 Mn |
| Dec 31, 2021 | 76.74 Mn |
| Sep 30, 2021 | 44.16 Mn |